English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims  To re‐analyse, using a series of alternative hypoglycaemia definitions, the data from 2 trials,  DUAL I  and  V , in which the once‐daily, fixed ratio combination of insulin degludec/liraglutide ( IDegLira ) was compared with basal insulin therapy.    Material and Methods   Post hoc  analyses of the  DUAL I  (patients uncontrolled on oral antidiabetic drugs) and  DUAL V  (patients uncontrolled on insulin glargine ( IGlar )  U100 ) trials were carried out using different definitions of hypoglycaemia and according to whether treatments were administered in the morning or afternoon. Rates of hypoglycaemia for the definitions of confirmed and  A merican  D iabetes Association ( ADA )‐documented symptomatic hypoglycaemia were compared according to age, gender and body mass index ( BMI ).    Results  Although hypoglycaemia rates differed according to the alternative hypoglycaemia definitions, rates were consistently lower with  IDegLira  vs insulin degludec ( IDeg ) and  IGlar U100 . Despite glycated haemoglobin concentrations being lower with  IDegLira  at end of treatment, confirmed and nocturnal‐confirmed hypoglycaemia rates were lower for  IDegLira  vs  IDeg  and  IGlar U100 , irrespective of dosing time. The definitions of confirmed and  ADA ‐documented symptomatic hypoglycaemia did not have a significant effect on the treatment difference between  IDegLira  and  IDeg , liraglutide or  IGlar U100  when further assessed by baseline age, gender and  BMI .    Conclusions  Treatment with  IDegLira , vs  IDeg  and  IGlar U100 , resulted in lower rates of hypoglycaemia regardless of dosing time and definition of hypoglycaemia used. The choice of hypoglycaemia definition did not influence the results of analyses when stratified by age, sex and  BMI .

diabetes, obesity and metabolism

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide ( IDegLira ) than with  IDeg  or insulin glargine, regardless of the hypoglycaemia definition used